RecruitingPhase 2NCT04778046

Pulmonary Hypertension SOLAR

Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH

Sponsor

Bastiaan Driehuys

Enrollment

30 participants

Start Date

Nov 8, 2023

Study Type

INTERVENTIONAL

Conditions

COPD Interstitial Lung Disease Pulmonary Arterial Hypertension

Summary

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study follows patients on the lung transplant waiting list at Duke University Medical Center who have pulmonary hypertension (high blood pressure in the lungs) — either from a primary lung condition like pulmonary arterial hypertension (PAH), COPD, or pulmonary fibrosis. The goal is to understand how high lung blood pressure behaves differently depending on its underlying cause. **You may be eligible if...** - You are 18 or older and on the lung transplant waiting list at Duke University Medical Center - You have pulmonary hypertension confirmed by a heart catheterization procedure, OR - You have COPD or pulmonary fibrosis with or without elevated lung pressure **You may NOT be eligible if...** - You are not being evaluated at Duke University Medical Center - You are unwilling or unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.